Skip to main content
. 2020 Aug 16;105(10):e3785–e3797. doi: 10.1210/clinem/dgaa526

Figure 1.

Figure 1.

Study design for the CHIASMA OPTIMAL trial, including screening, DPC period, and OLE. DPC, double-blind placebo-controlled; IGF-1, insulin-like growth factor 1; OLE, open-label extension; OOC, oral octreotide capsules; SRL, somatostatin receptor ligand; SV, screening visit.